Why this pharma pro likes Johnson & Johnson, Eli Lilly, and Merck stock

Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.

Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.

Source: MSN The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.